



September 22, 2016

Five Prime Therapeutics to Present at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable

SOUTH SAN FRANCISCO, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable on Thursday, September 29, 2016, at 11:00 AM Eastern Daylight Time.

The live webcast will be accessible at <http://investor.fiveprime.com/events.cfm> or directly at <http://wsw.com/webcast/leerink27/fprx>. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.

CONTACT:

Heather Rowe, Investor Relations

415-365-5737

heather.rowe@fiveprime.com

 Primary Logo

Source: Five Prime Therapeutics, Inc.

News Provided by Acquire Media